<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777140</url>
  </required_header>
  <id_info>
    <org_study_id>TANDEM-1</org_study_id>
    <secondary_id>EUDRACT: 2007-006731-31</secondary_id>
    <nct_id>NCT00777140</nct_id>
  </id_info>
  <brief_title>Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion</brief_title>
  <acronym>TANDEM-1</acronym>
  <official_title>Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Institut Germans Trias i Pujol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron overload has been associated with greater brain injury in ischemia/reperfusion
      experimental stroke models and ischemic stroke patients, especially in those treated with
      thrombolytic treatment. Deferoxamine administration, an iron chelator, offers a
      neuroprotective action in ischemia/reperfusion animal models.

      Primary objective: To evaluate the security and tolerability of deferoxamine endovenous
      treatment in acute ischemic stroke patients treated with iv. tPA.

      Secondary objectives: To study pharmacokinetics of deferoxamine given by endovenous bolus (10
      mg/Kg) followed by 72-hour continuous intravenous infusion (20, 40 o 60 mg/Kg). To evaluate
      the deferoxamine effect in clinical outcome, infarct volume and hemorrhagic transformation
      and brain edema development.

      Methodology: Double-blind, randomized, placebo controlled, dose-finding phase II clinical
      trial. Study stages: 1st: bolus+20 mg/Kg/day vs. Placebo (n=15:5); 2nd: bolus+40 mg/Kg/day
      vs. Placebo (n=15:5); 3rd: bolus+60 mg/Kg/day vs placebo (n=15:5). These doses will be
      increased according to security results of the previous stage. Patients will be continuously
      monitored in stroke units. Laboratory parameters will be measured at baseline, 24h, 72h and
      30 days to evaluate adverse events related to the drug. Serum deferoxamine and feroxamine
      concentrations will be measured along time after the injection in a subgroup of patients to
      the pharmacokinetics study. CT scan will be performed at 24-36h to assess hemorrhagic
      transformation and brain edema. The NIH Stroke Scale will be evaluated during
      hospitalization, and the Rankin score at discharge and 3 months.

      If deferoxamine demonstrate to be secure and well tolerated treatment in acute stroke
      patients, it may be a new therapy option to lower the brain injury after ischemia and
      reperfusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Analytical Adverse Events (anemia, hypotension, renal failure, mortality, hemorrhagic transformation, cerebral edema, other severe adverse events)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological status (NIHSS, Barthel and Rankin scales), final ischemic lesion volume on CTscan.</measure>
    <time_frame>24h, 7days and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deferoxamine and ferritin levels in serum (pharmacokinetics).</measure>
    <time_frame>72h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1. Deferoxamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <description>Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.
Bolus + 72h perfusion of saline solution for the placebo group.</description>
    <arm_group_label>1. Deferoxamine</arm_group_label>
    <arm_group_label>2. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years old

          -  Acute Ischemic Stroke on the middle cerebral artery territory

          -  Treatment with iv tPA in the first 3 hours from symptoms onset

        Exclusion Criteria:

          -  Modified Rankin Scale more or equal to 2

          -  Infectious, inflammatory, neoplastic or hematologic disease

          -  Anemia (Hto&lt;34% or Hb&lt;10g/dl)

          -  Previous renal failure

          -  Previous treatment with oral iron supplement

          -  Minor stroke (NIHSS less than 4), lacunar or posterior territory

          -  Alcohol consumption (more than 40mg/Kg)

          -  Pregnancy

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Millán Torné, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña, Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kontos HA. Oxygen radicals in cerebral ischemia: the 2001 Willis lecture. Stroke. 2001 Nov;32(11):2712-6.</citation>
    <PMID>11692043</PMID>
  </reference>
  <reference>
    <citation>Selim MH, Ratan RR. The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev. 2004 Jul;3(3):345-53. Review.</citation>
    <PMID>15231241</PMID>
  </reference>
  <reference>
    <citation>Castellanos M, Puig N, Carbonell T, Castillo J, Martinez J, Rama R, Dávalos A. Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. Brain Res. 2002 Oct 11;952(1):1-6.</citation>
    <PMID>12363398</PMID>
  </reference>
  <reference>
    <citation>Millan M, Sobrino T, Castellanos M, Nombela F, Arenillas JF, Riva E, Cristobo I, García MM, Vivancos J, Serena J, Moro MA, Castillo J, Dávalos A. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007 Jan;38(1):90-5. Epub 2006 Nov 30.</citation>
    <PMID>17138950</PMID>
  </reference>
  <reference>
    <citation>Dávalos A, Castillo J, Marrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, Rama R. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology. 2000 Apr 25;54(8):1568-74.</citation>
    <PMID>10762495</PMID>
  </reference>
  <reference>
    <citation>Dávalos A, Fernandez-Real JM, Ricart W, Soler S, Molins A, Planas E, Genís D. Iron-related damage in acute ischemic stroke. Stroke. 1994 Aug;25(8):1543-6. Erratum in: Stroke 1994 Nov;25(11):2300.</citation>
    <PMID>8042204</PMID>
  </reference>
  <reference>
    <citation>Erdemoglu AK, Ozbakir S. Serum ferritin levels and early prognosis of stroke. Eur J Neurol. 2002 Nov;9(6):633-7.</citation>
    <PMID>12453079</PMID>
  </reference>
  <reference>
    <citation>Soloniuk DS, Perkins E, Wilson JR. Use of allopurinol and deferoxamine in cellular protection during ischemia. Surg Neurol. 1992 Aug;38(2):110-3.</citation>
    <PMID>1509342</PMID>
  </reference>
  <reference>
    <citation>Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg. 1990 Feb;25(2):224-7; discussion 227-8.</citation>
    <PMID>2303992</PMID>
  </reference>
  <reference>
    <citation>Palmer C, Roberts RL, Bero C. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke. 1994 May;25(5):1039-45.</citation>
    <PMID>8165675</PMID>
  </reference>
  <reference>
    <citation>Hurn PD, Koehler RC, Blizzard KK, Traystman RJ. Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke. 1995 Apr;26(4):688-94; discussion 694-5.</citation>
    <PMID>7709418</PMID>
  </reference>
  <reference>
    <citation>Freret T, Valable S, Chazalviel L, Saulnier R, Mackenzie ET, Petit E, Bernaudin M, Boulouard M, Schumann-Bard P. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci. 2006 Apr;23(7):1757-65.</citation>
    <PMID>16623832</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Hida H, Jung CG, Miura Y, Nishino H. Treatment with deferoxamine increases neurons from neural stem/progenitor cells. Brain Res. 2006 May 30;1092(1):1-15. Epub 2006 May 12.</citation>
    <PMID>16697980</PMID>
  </reference>
  <reference>
    <citation>Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol. 1979 Aug;42(4):547-55.</citation>
    <PMID>476006</PMID>
  </reference>
  <reference>
    <citation>Allain P, Mauras Y, Chaleil D, Simon P, Ang KS, Cam G, Le Mignon L, Simon M. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol. 1987 Aug;24(2):207-12.</citation>
    <PMID>3620295</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Monica Millan Torne</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombolytic treatment</keyword>
  <keyword>Middle cerebral artery occlusion</keyword>
  <keyword>Deferoxamine</keyword>
  <keyword>Iron chelator</keyword>
  <keyword>Acute Ischemic Stroke treated with Intravenous Thrombolytic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Fibrinolytic Agents</mesh_term>
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

